About Celsius Therapeutics
Celsius Therapeutics operates as a biotechnology company. It applies a systematic approach to single-cell sequencing, combining datasets and algorithms to discover precision therapies. The company was founded in 2018 and is based in Cambridge, Massachusetts.
ESPs containing Celsius Therapeutics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The single cell analysis platforms market is an emerging field that offers solutions for the study of individual cells in various biological systems. This market offers a range of platforms, including microfluidic devices, imaging systems, and sequencing technologies, that enable the isolation, characterization, and analysis of single cells. By using single cell analysis platforms, researchers can…
Celsius Therapeutics's Products & Differentiators
AI and Single Cell Enabled Novel Therapeutic (ASCENT) platform
Industrialized single cell genomics methods
Research containing Celsius Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Celsius Therapeutics in 1 CB Insights research brief, most recently on Sep 19, 2022.
Expert Collections containing Celsius Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Celsius Therapeutics is included in 4 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Latest Celsius Therapeutics News
Aug 4, 2023
The study’s primary outcome measures include treatment-emergent adverse events. CEL383 is intended for the treatment of inflammatory bowel disease. Credit: sdecorated/Shutterstock.com. Celsius Therapeutics has initiated the dosing of healthy volunteers in its first-in-human Phase I clinical trial of CEL383 to treat inflammatory bowel disease (IBD). The single ascending dose, placebo-controlled, double-blind, randomised study is designed to assess the pharmacokinetics, tolerability, and safety of the anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody CEL383. Recommended Reports The study’s primary outcome measures include treatment-emergent adverse events. Cmax, Tmax, t1/2, area under the curve, and incidences of anti-drug antibodies, as determined after a single ascending dose through day one to day 85, are the secondary outcome measures. The study also includes an exploratory assessment of target engagement, as measured by receptor occupancy. Celsius president and CEO Tariq Kassum said: “The initiation of this study marks an important milestone for Celsius as we advance the first clinical candidate identified through our SCOPE platform into the clinic. “A substantial and growing body of evidence shows that TREM-1 plays a central role in ulcerative colitis and Crohn’s disease, chronic inflammatory conditions that can significantly impact patient lives. “We believe a precision therapy like CEL383 has the potential to offer a clinically meaningful treatment option that could improve the quality of life for people suffering with IBD.” Celsius’ first clinical candidate CEL383 inhibits TREM1 signalling and reduces levels of multiple inflammatory mediators such as TNFα and IL23. The company is engaged in developing precision medicines for treating inflammatory disease by using single cell RNA sequencing and human biology at scale. Share this article
Celsius Therapeutics Frequently Asked Questions (FAQ)
When was Celsius Therapeutics founded?
Celsius Therapeutics was founded in 2018.
Where is Celsius Therapeutics's headquarters?
Celsius Therapeutics's headquarters is located at 399 Binney Street, Cambridge.
What is Celsius Therapeutics's latest funding round?
Celsius Therapeutics's latest funding round is Series B.
How much did Celsius Therapeutics raise?
Celsius Therapeutics raised a total of $148M.
Who are the investors of Celsius Therapeutics?
Investors of Celsius Therapeutics include Casdin Capital, Heritage Provider Network, Alexandria Venture Investments, Google Ventures, Third Rock Ventures and 8 more.
Who are Celsius Therapeutics's competitors?
Competitors of Celsius Therapeutics include Cellarity and 7 more.
What products does Celsius Therapeutics offer?
Celsius Therapeutics's products include AI and Single Cell Enabled Novel Therapeutic (ASCENT) platform and 2 more.
Who are Celsius Therapeutics's customers?
Customers of Celsius Therapeutics include Servier, University of Oxford, Cleveland Clinic, LMU University Hospital Munich, Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy and the University Health Network and Janssen.
Compare Celsius Therapeutics to Competitors
AliveX is a company focused on the intersection of computational biology and drug development, operating within the biotechnology and pharmaceutical industries. The company's main service involves the generation and combination of multi-omics data with computational biology and Model-Informed Drug Development (MIDD) to enhance the success rate of drug development for immune-mediated diseases. AliveX primarily serves the biotechnology and pharmaceutical sectors. It was founded in 2019 and is based in Zurich, Switzerland.
Ochre Bio operates as a biotechnology company developing ribonucleic acid (RNA) medicines for chronic liver diseases. It uses genomic deep phenotyping precision RNA medicine and testing in live human donor livers to develop therapies for liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. The company was founded in 2019 and is based in Oxford, United Kingdom.
Quris AI is an innovator in the field of artificial intelligence, with a specific focus on disrupting the drug development process. The company's main service is its Bio-AI Clinical Prediction Platform, which uses machine learning to predict the safety and efficacy of drug candidates, aiming to reduce the costs associated with failed clinical trials. Quris AI primarily serves the pharmaceutical industry. It was founded in 2019 and is based in Tel-Aviv, Israel.
Arctoris develops an automated drug discovery company. It combines its unique automation platform, Ulysses, with advanced machine learning approaches and a team of seasoned drug hunters to guide and progress drug discovery programs in oncology and neurology. It offers on-demand access to various drug discovery assays conducted by robotics to biotech companies, pharmaceutical corporations, and academic centers. It was founded in 2016 and is based in Oxfordshire, United Kingdom.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI Foundation Models to understand and predict complex biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.